Geode Capital Management LLC Sells 42,275 Shares of Context Therapeutics Inc. (NASDAQ:CNTX)

Geode Capital Management LLC decreased its position in shares of Context Therapeutics Inc. (NASDAQ:CNTX) by 6.8% in the third quarter, HoldingsChannel reports. The firm owned 575,899 shares of the company’s stock after selling 42,275 shares during the quarter. Geode Capital Management LLC’s holdings in Context Therapeutics were worth $1,129,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Renaissance Technologies LLC grew its holdings in Context Therapeutics by 63.4% during the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after buying an additional 25,300 shares in the last quarter. Ally Bridge Group NY LLC boosted its position in shares of Context Therapeutics by 159.8% during the 2nd quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock valued at $3,782,000 after acquiring an additional 1,160,281 shares during the last quarter. Great Point Partners LLC purchased a new position in shares of Context Therapeutics in the second quarter valued at $14,876,000. Affinity Asset Advisors LLC increased its position in Context Therapeutics by 392.4% in the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after purchasing an additional 1,290,323 shares during the last quarter. Finally, Blue Owl Capital Holdings LP purchased a new stake in Context Therapeutics during the second quarter valued at $10,348,000. 14.03% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CNTX has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Context Therapeutics in a report on Monday, September 23rd. Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a research note on Wednesday. D. Boral Capital initiated coverage on Context Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $9.00 target price for the company. Finally, JMP Securities started coverage on Context Therapeutics in a report on Wednesday. They set an “outperform” rating and a $4.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $6.33.

Context Therapeutics Price Performance

Shares of Context Therapeutics stock opened at $1.21 on Friday. Context Therapeutics Inc. has a 1 year low of $0.89 and a 1 year high of $2.75. The stock has a market cap of $90.75 million, a PE ratio of -1.33 and a beta of 2.10. The firm has a fifty day moving average price of $1.50 and a 200 day moving average price of $1.93.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.11). As a group, equities analysts expect that Context Therapeutics Inc. will post -0.51 EPS for the current year.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.